Search
aTyr Pharma Inc
ATYRAdd to Watchlist
0.486USD
+0.006+1.19%
Close 07-31 16:00（ET）Quotes delayed by 15 min
47.59MMarket Cap
LossP/E TTM
More Details of aTyr Pharma Inc Company
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).
aTyr Pharma Inc Info
Ticker SymbolATYR
Company nameaTyr Pharma Inc
IPO dateMay 07, 2015
CEOShukla (Sanjay S)
Number of employees56
Security typeOrdinary Share
Fiscal year-endMay 07
Address10240 Sorrento Valley Road
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18587318389
Websitehttps://www.atyrpharma.com/
Ticker SymbolATYR
IPO dateMay 07, 2015
CEOShukla (Sanjay S)
Company Executives of aTyr Pharma Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Sanjay S. Shukla, M.D.
Dr. Sanjay S. Shukla, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
153.55K
--
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
56.00K
--
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
9.75K
--
Dr. Svetlana Lucas, Ph.D.
Dr. Svetlana Lucas, Ph.D.
Independent Director
Independent Director
6.00K
--
Dr. Paul R. Schimmel, Ph.D.
Dr. Paul R. Schimmel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jill M. Broadfoot
Ms. Jill M. Broadfoot
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Nancy E. Denyes, J.D.
Ms. Nancy E. Denyes, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Sara A. Zaknoen, M.D.
Dr. Sara A. Zaknoen, M.D.
Independent Director
Independent Director
--
--
Mr. Eric S. Benevich
Mr. Eric S. Benevich
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Sanjay S. Shukla, M.D.
Dr. Sanjay S. Shukla, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
153.55K
--
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
56.00K
--
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
9.75K
--
Dr. Svetlana Lucas, Ph.D.
Dr. Svetlana Lucas, Ph.D.
Independent Director
Independent Director
6.00K
--
Dr. Paul R. Schimmel, Ph.D.
Dr. Paul R. Schimmel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jill M. Broadfoot
Ms. Jill M. Broadfoot
Chief Financial Officer
Chief Financial Officer
--
--
FAQs
Who are the top five shareholders of aTyr Pharma Inc?
The top five shareholders of aTyr Pharma Inc are: Dr. Sanjay S. Shukla, M.D.
How many institutions hold shares of aTyr Pharma Inc (ATYR)?
As of 2026Q1, 263 institutions hold shares of aTyr Pharma Inc, with a combined market value of approximately 55.62M, accounting for 56.72% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -22623140.00.